Mar. 19 at 1:15 PM
$XERS All analysts either raised their ratings or maintained their initial ratings since the last review, while the stock declined despite the company's outstanding success.
I believe they may need to raise their ratings even further soon, for two main reasons that I see as likely:
A)Revenue Growth & Margins
The rapid uptake of Recorlev, I believe, has only just begun. Last year was the first year Recorlev demonstrated that it is the primary growth driver in Cushing's treatment (in the direct cortisol-lowering segment). It is becoming a broad and expanding market. Gvoke is growing steadily. Keveyis remains stable. There is income from VialDX, as well as new revenue from the U.S. VA. With margins now around 87%, there is a significant financial difference compared to 82%–85%, especially when discussing ~
$400M in revenue. All of this would translate into self-sustainability.
B)XP-8121
No one will be able to ignore XP-8121 in Phase 3. It has the potential to be a 2–3 BB.
